ReviewCureus2025
Basal Ganglia Calcifications for Nephrologists: Fahr/Primary Familial Brain Calcification (PFBC) at the Interface of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) and Hypoparathyroidism.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilateral basal ganglia calcifications are increasingly recognized on neuroimaging, yet their interface with chronic kidney disease-mineral and bone disorder (CKD-MBD) and hypoparathyroidism is rarely addressed from a nephrology perspective. In this narrative review, we synthesized data on primary familial brain calcification (PFBC) and secondary Fahr syndromes, highlight proposed mechanisms linking disturbances in calcium-phosphate-parathyroid hormone (PTH) homeostasis to intracranial parenchymal calcification, and summarize the clinical spectrum from incidental findings to disabling movement, cognitive, and psychiatric manifestations. Targeted searches of the literature and relevant guidelines were used to integrate mechanistic, imaging, and clinical studies with the authors' nephrology experience. Evidence suggests that chronic hypocalcemia with relative hyperphosphatemia in hypoparathyroidism and disordered calcium-phosphate-PTH balance in CKD-MBD (typically secondary hyperparathyroidism) may lower the threshold for basal ganglia mineralization. Symptom control and early metabolic correction can improve neurological outcomes even though radiologic calcifications usually persist. Direct data in dialysis and transplant cohorts remain sparse, representing a major research gap. We propose a pragmatic, nephrology-focused approach: confirm the radiologic pattern, obtain a compact mineral panel in all patients, treat reversible metabolic causes before extensive testing, and reserve PFBC genetic panels for compatible phenotypes and family histories. This framework aims to make basal ganglia calcifications a more familiar and actionable finding in kidney practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.